Abraxis BioScience to Present at the Merriman Curhan Ford Investor Summit and Lazard Capital Markets Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated, global biotechnology company, announced today that management will present a company overview at the following two upcoming conferences:

A live webcast of each presentation will be available in the Investor Relations section of the company’s website at www.abraxisbio.com. The webcasts will be archived and accessible for at least 30 days.

About Abraxis BioScience

Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE^®), which is based on the company's proprietary tumor targeting technology known as the nab^® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 38 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.

Investor & Media Inquiries
Abraxis BioScience, Inc.
Maili Bergman
Director Investor Relations & Corporate Communications
310-883-1300
investorrelations@abraxisbio.com
or
PondelWilkinson Inc.
Rob Whetstone, 310-279-5963